Active surveillance for adverse events following immunization

Expert Review of Vaccines
Nigel W CrawfordJim P Buttery

Abstract

Comprehensive surveillance of adverse events following immunization (AEFI) is required to detect potential serious adverse events that may not be identified in prelicensure vaccine trials. Surveillance systems have traditionally been passive, relying upon spontaneous reporting, but increasingly active surveillance and supplemental strategies are being incorporated into vaccine safety programs. These include active screening for targeted conditions of interest (e.g., hospitalization), monitoring of new data sources and real-time methodologies to detect changes in vaccine safety data in these sources. The role of improved causality assessment in AEFI surveillance is discussed, with its important role in determining whether a temporal association may have occurred by chance alone. Strong local vaccine safety networks are required to support national immunization programs, with recent progress in developing a framework for low- and middle-income countries. Global collaboration is increasingly required to address challenges in active AEFI surveillance, particularly for rare serious adverse events.

References

Dec 1, 1991·The Journal of Pathology·P A Wright, D Wynford-Thomas
Dec 1, 1995·American Journal of Public Health·S Rosenthal, R Chen
Feb 24, 2001·Archives of Disease in Childhood·E MillerB Taylor
Feb 24, 2001·The New England Journal of Medicine·T V MurphyUNKNOWN Rotavirus Intussusception Investigation Team
Jun 20, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Andrew BateRoland Orre
Nov 8, 2002·The New England Journal of Medicine·Kreesten Meldgaard MadsenMads Melbye
Dec 10, 2002·Annual Review of Public Health·Gerard Rushton
Dec 19, 2002·Archives of Insect Biochemistry and Physiology·Hasan TunazDavid W Stanley
May 7, 2003·New South Wales Public Health Bulletin·Glenda LawrenceGay Rixon
Apr 9, 2004·The New England Journal of Medicine·Anders HviidMads Melbye
May 4, 2004·Vaccine·Jan BonhoefferUNKNOWN Brighton Collaboration
Apr 9, 2005·Journal of Paediatrics and Child Health·David IsaacsJohn McEwen
Nov 8, 2005·Lancet·Richard A C Hughes, David R Cornblath
May 13, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·John IskanderUNKNOWN VAERS Team
Jan 19, 2008·Clinical Microbiology Reviews·Penelope H Dennehy
Mar 4, 2008·Pediatrics·Eric K FranceUNKNOWN Vaccine Safety Datalink Team
Jun 20, 2008·Statistical Methods in Medical Research·Heather J WhitakerC Paddy Farrington
Sep 3, 2008·Pediatrics·Robert A WoodUNKNOWN Hypersensitivity Working Group of the Clinical Immunization Safety Assessment (CISA) Network
Dec 9, 2008·Vaccine·Jan BonhoefferUNKNOWN Brighton Collaboration Methods Working Group
Aug 20, 2009·JAMA : the Journal of the American Medical Association·Barbara A SladeJohn Iskander
Sep 17, 2009·The Pediatric Infectious Disease Journal·Wei HuaRobert Ball
Oct 13, 2009·The Journal of Infectious Diseases·Julie E BinesUmesh Parashar
Nov 27, 2009·The New England Journal of Medicine·James F BishopRhonda Owen
May 1, 2010·Bulletin of the World Health Organization·Mark HatherillGregory Hussey
May 8, 2010·Lancet Neurology·Anne M McIntoshSamuel F Berkovic
Jul 1, 2010·Pediatrics·Nicola P KleinUNKNOWN Vaccine Safety Datalink
Jul 8, 2010·Australian Dental Journal·UNKNOWN Australian Research Centre for Population Oral Health
Sep 14, 2010·Epilepsia·Andrew Escayg, Alan L Goldin
Sep 14, 2010·Vaccine·Gregory A Poland
Oct 5, 2010·Australian Dental Journal·UNKNOWN Australian Research Centre for Population Oral Health, The University of Adelaide, South Australia
Dec 24, 2010·Australian Dental Journal·UNKNOWN Australian Research Centre for Population Oral Health, The University of Adelaide, South Australia

❮ Previous
Next ❯

Citations

Dec 9, 2014·Human Vaccines & Immunotherapeutics·Hazel J ClothierJim P Buttery
Mar 18, 2016·Expert Opinion on Drug Safety·Nicola Principi, Susanna Esposito
Jun 14, 2016·Human Vaccines & Immunotherapeutics·Nigel W CrawfordUNKNOWN AEFI-CAN network
Nov 12, 2016·Vaccine·Alberta Di PasqualeFernanda Tavares Da Silva
May 30, 2017·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Hazel J ClothierJim P Buttery
Dec 6, 2014·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Hazel J ClothierJim P Buttery
Mar 28, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Hazel J ClothierJim P Buttery
Dec 24, 2018·BMC Public Health·Stefania Spila AlegianiCaterina Rizzo
Jun 20, 2021·BMJ : British Medical Journal·Vincent Lo ReAlmut G Winterstein
Jan 14, 2019··Pari Delir HaghighiSedigheh Khademi Habibabadi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.